This trial investigates the use of Daratumumab (DARA), an antibody directed at the human
cluster of differentiation 38 (CD38) molecule, for the treatment of patients with
Polyneuropathy, Organomegaly, Endocrinopathy, m Protein Component, Skin Changes (POEMS)
syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA,
in combination with the immunomodulatory drug (IMiD) lenalidomide. Objectives of this study
include improvement in neuropathy and performance status, as well as improvement in
laboratory values and survival.